Genfit S.A. - Asset Resilience Ratio
Genfit S.A. (GNFT) has an Asset Resilience Ratio of 5.12% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Genfit S.A. carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2024)
This chart shows how Genfit S.A.'s Asset Resilience Ratio has changed over time. See Genfit S.A. book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Genfit S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see GNFT market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €11.09 Million | 5.12% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €11.09 Million | 5.12% |
Asset Resilience Insights
- Limited Liquidity: Genfit S.A. maintains only 5.12% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Genfit S.A. Industry Peers by Asset Resilience Ratio
Compare Genfit S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Genfit S.A. (2004–2024)
The table below shows the annual Asset Resilience Ratio data for Genfit S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 42.40% | €64.21 Million ≈ $75.07 Million |
€151.42 Million ≈ $177.03 Million |
+3.56pp |
| 2023-12-31 | 38.84% | €67.53 Million ≈ $78.95 Million |
€173.87 Million ≈ $203.27 Million |
-18.52pp |
| 2022-12-31 | 57.36% | €123.64 Million ≈ $144.55 Million |
€215.54 Million ≈ $251.99 Million |
+33.13pp |
| 2021-12-31 | 24.23% | €68.26 Million ≈ $79.80 Million |
€281.72 Million ≈ $329.36 Million |
-59.37pp |
| 2020-12-31 | 83.60% | €166.03 Million ≈ $194.11 Million |
€198.61 Million ≈ $232.20 Million |
-1.33pp |
| 2019-12-31 | 84.93% | €263.15 Million ≈ $307.65 Million |
€309.85 Million ≈ $362.25 Million |
-5.69pp |
| 2016-12-31 | 90.61% | €150.61 Million ≈ $176.08 Million |
€166.21 Million ≈ $194.32 Million |
+90.58pp |
| 2015-12-31 | 0.03% | €22.00K ≈ $25.72K |
€69.26 Million ≈ $80.97 Million |
-4.61pp |
| 2014-12-31 | 4.64% | €4.01 Million ≈ $4.69 Million |
€86.37 Million ≈ $100.97 Million |
+4.64pp |
| 2013-12-31 | 0.00% | €400.00 ≈ $467.64 |
€29.15 Million ≈ $34.08 Million |
-0.07pp |
| 2012-12-31 | 0.08% | €18.00K ≈ $21.04K |
€23.58 Million ≈ $27.57 Million |
+0.03pp |
| 2011-12-31 | 0.05% | €13.80K ≈ $16.13K |
€29.08 Million ≈ $33.99 Million |
-1.96pp |
| 2008-12-31 | 2.00% | €921.40K ≈ $1.08 Million |
€45.99 Million ≈ $53.77 Million |
-1.85pp |
| 2007-12-31 | 3.85% | €1.55 Million ≈ $1.81 Million |
€40.21 Million ≈ $47.01 Million |
+0.60pp |
| 2006-12-31 | 3.25% | €1.50 Million ≈ $1.76 Million |
€46.24 Million ≈ $54.06 Million |
-2.21pp |
| 2005-12-31 | 5.46% | €1.68 Million ≈ $1.97 Million |
€30.83 Million ≈ $36.05 Million |
-33.51pp |
| 2004-12-31 | 38.96% | €11.93 Million ≈ $13.94 Million |
€30.61 Million ≈ $35.78 Million |
-- |
About Genfit S.A.
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fi… Read more